A comparative study on the effects of a contraceptive vaginal ring NuvaRing^® and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function

Abstract

Objectives To compare carbohydrate metabolism, adrenal and thyroid function during use of a combined contraceptive vaginal ring (NuvaRing®, NV Organon, Oss, The Netherlands) with those of a combined oral contraceptive. Methods Healthy women aged 18-40 years used either the vaginal ring, delivering 15 μg ethinylestradiol and 120 μg of etonogestrel per day, or a combined oral contraceptive containing 30 μg ethinylestradiol and 150 μg levonorgestrel, for six cycles. Each cycle comprised 3 weeks of use of the ring or the pill followed by 1 ring- or pill-free week. The following parameters were measured at baseline and at the end of cycles 3 and 6: carbohydrate metabolism (glucose, insulin, glycosylated hemoglobin); adrenal function (total cortisol, cortisol binding globulin, dehydroepiandrosterone sulfate); thyroid function (thyroid stimulating hormone, free thyroxine). Results Small and similar increases in insulin were seen in both groups. Concentrations of cortisol binding globulin and total cortisol rose significantly less during ring use than during combined oral contraceptive use (cycle 3, p = 0.0002; cycle 6, p < 0.0001). Levels of dehydroepiandrosterone sulfate did not change in either group. Thyroid stimulating hormone levels increased significantly more in the ring group at cycle 3 (p = 0.0016) but free thyroxine levels were unchanged in both groups. Conclusions Both the vaginal ring and the oral contraceptive have no clinically relevant effects on carbohydrate metabolism, adrenal or thyroid function.

• Nuvaring
• Carbohydrate
• Adrenal
• Thyroid
• Vaginal Ring
• Contraceptive
• Safety